Trial Profile
A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Interstitial lung diseases; Myositis
- Focus Proof of concept; Therapeutic Use
- Acronyms ATtackMy-ILD
- 30 May 2023 Planned End Date changed from 31 Mar 2023 to 30 Jul 2023.
- 31 Oct 2022 Planned End Date changed from 30 Sep 2022 to 31 Mar 2023.
- 10 Jul 2022 Planned End Date changed from 30 May 2023 to 30 Sep 2022.